Sugar supplement may calm seizures and stomach troubles in rare genetic disease
NCT ID NCT05402384
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether a sugar called D-galactose (AVTX-801) can help people with SLC35A2-CDG, a rare inherited disorder that disrupts how the body adds sugar to proteins. The trial enrolls about 10 people of any age who have seizures or chronic digestive issues. Participants receive either D-galactose or a placebo in a crossover design, so everyone gets both over time. The goal is to see if the supplement reduces seizure frequency and improves stool consistency.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D-galactose (AVTX-801)
- What this could lead to
- If it works, this could point toward a treatment that reduces seizures and digestive problems in people with SLC35A2-CDG.
- What could go wrong
- This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The supplement may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLC35A2-CDG - SOLUTE CARRIER FAMILY 35 MEMBER A2 CONGENITAL DISORDER OF GLYCOSYLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States